Physician profile
Mihail M Subtirelu
NPI 1487675831
$2,043.51
in general payments reported to CMS, 2019-2025
16 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Pediatric Nephrology provider received nationally (typical 2025 total: $131).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $216 · 2021: $251 · 2022: $544 · 2023: $268 · 2024: $127 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $797 · Education: $5.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $796.84 |
| Education | $5.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $427.30 | 2019-2023 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $345.22 | 2020-2025 | Acthar |
| Genzyme Corporation | $282.10 | 2022-2025 | |
| Azurity Pharmaceuticals, INC. | $203.48 | 2020-2025 | Katerzia |
| Mallinckrodt Enterprises LLC | $174.16 | 2019 | |
| Aurinia Pharma U.S., INC. | $141.25 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $131.70 | 2020-2021 | |
| Cmp Pharma, INC. | $93.94 | 2022-2023 | Norliqva |
| Kyowa Kirin, INC. | $68.88 | 2023-2025 | Crysvita |
| Novartis Pharmaceuticals Corporation | $53.00 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $25.94 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $22.56 | 2025 | Givlaari |
| Travere Therapeutics, INC. | $22.49 | 2023-2025 | Cholbam, Thiola |
| Apellis Pharmaceuticals, INC. | $22.31 | 2025 | Empaveli |
| Exeltis, USA INC. | $15.50 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Palette Life Sciences, INC. | $13.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mihail Subtirelu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.